Genetic Evidence for GLP ‐1 and GIP Receptors as Targets for Treatment and Prevention of MASLD / MASH
Liver International · 2025
DOI: 10.1111/liv.16150 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Ran Yan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Receptors, Gastrointestinal Hormone, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province, Taishan Scholar Project of Shandong Province.
Abstract (Originalsprache)
Background and Aims Glucagon‐like peptide‐1 receptor (GLP1R) agonists and glucose‐dependent insulinotropic polypeptide receptor (GIPR) agonists may help treat metabolic dysfunction‐associated steatotic liver disease (MASLD) and metabolic dysfunction‐associated steatohepatitis (MASH). However, their definitive effects are still unclear. Our study aims to clarify this uncertainty.
Methods
We utilised conventional Mendelian randomisation (MR) analysis to explore potential causal links between plasma GLP‐1/GIP concentrations and MASLD and its related traits. Next, we conducted drug‐target MR analysis using highly expressed tissue data to assess the effects of corresponding drug perturbation on these traits. Finally, mediation analysis was performed to ascertain whether the potential causal effect is direct or mediated by other MASLD‐related traits.
Results
Circulating 2‐h GLP‐1 and GIP concentrations measured during an oral glucose tolerance test showed hepatoprotective effects on MASLD risk (OR GLP‐1 = 0.168 [95% CI 0.033–0.839], p = 0.030; OR GIP = 0.331 [95% CI 0.222–0.494], p = 6.31 × 10 −8 ). GLP1R expression in the blood had a minimal causal effect on MASLD risk, whereas GIPR expression significantly affected MASLD risk (OR = 0.671 [95% CI 0.531–0.849], p = 9.07 × 10 −4 ). Expression levels of GLP1R or GIPR in the blood significantly influenced MASLD‐related clinical traits. Mediation analysis revealed that GIPR expression protected against MASLD, even after adjusting for type 2 diabetes or body mass index.
Conclusions
GLP‐1/GIP receptor agonists offer promise in lowering MASLD/MASH risk. GIP receptor agonists can exert direct and indirect effects on MASLD mediated by weight reduction or glycemic control improvement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
- Institute for Medical Dataology, Shandong University, Jinan, Shandong, China.
- Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.
- Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, USA.
- Centre for Systems Biology, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
ORCID-Profile: Giovanni Targher, Jian Zhao
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Taishan Scholar Project of Shandong Province
- Shenzhen Medical Research Fund
- Cheeloo Young Talent Program of Shandong University
- Taishan Scholar Foundation of Shandong Province
Zitieren
APA
Yan, R., Liu, L., Tzoulaki, I., Fan, J., Targher, G., Yuan, Z., & Zhao, J. (2025). Genetic Evidence for GLP ‐1 and GIP Receptors as Targets for Treatment and Prevention of MASLD / MASH. Liver International. https://doi.org/10.1111/liv.16150
Vancouver
Yan R, Liu L, Tzoulaki I, Fan J, Targher G, Yuan Z, et al. Genetic Evidence for GLP ‐1 and GIP Receptors as Targets for Treatment and Prevention of MASLD / MASH. Liver International. 2025. doi:10.1111/liv.16150
BibTeX
@article{Yan2025,
author = {Yan, Ran and Liu, Lu and Tzoulaki, Ioanna and Fan, Jiangao and Targher, Giovanni and Yuan, Zhongshang and Zhao, Jian},
title = {Genetic Evidence for GLP ‐1 and GIP Receptors as Targets for Treatment and Prevention of MASLD / MASH},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.16150}
}
EUVIMED